{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:34:35Z","timestamp":1762673675076,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":5090,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.exphem.2008.01.006","type":"journal-article","created":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T14:30:52Z","timestamp":1210084252000},"page":"773-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Alternative treatment paradigm for thalassemia using iron chelators"],"prefix":"10.1016","volume":"36","author":[{"given":"Natasha","family":"Szuber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan L.","family":"Buss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Soe-Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hady","family":"Felfly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Ponka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2008.01.006_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1196\/annals.1345.024","article-title":"Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up","volume":"1054","author":"Gaziev","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.exphem.2008.01.006_bib2","first-page":"51","article-title":"The sickle erythrocyte in double jeopardy: autoxidation and iron decompartmentalization","volume":"27","author":"Hebbel","year":"1990","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0950-3536(98)80072-3","article-title":"Pathophysiology of thalassemia","volume":"11","author":"Weatherall","year":"1998","journal-title":"Bailli\u00e8re's Clin Haematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0037-1963(01)90028-9","article-title":"Pathophysiology of \u03b1- and \u03b2-thalassemia: therapeutic implications","volume":"38","author":"Rund","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib5","first-page":"352","article-title":"Excess \u03b1 chains are lost from \u03b2-thalassemic reticulocytes by proteolysis","volume":"98","author":"Testa","year":"1981","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/hmg\/7.10.1655","article-title":"The therapeutic reactivation of fetal haemoglobin","volume":"10","author":"Olivieri","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.exphem.2008.01.006_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1196\/annals.1345.013","article-title":"Role of alpha-hemoglobin stabilizing protein in normal erythropoiesis and beta-thalassemia","volume":"1054","author":"Weiss","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.exphem.2008.01.006_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.1983.00353.x-i1","article-title":"Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia","volume":"53","author":"Wainscoat","year":"1983","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib9","first-page":"441","article-title":"Denaturation of the normal and abnormal hemoglobin molecule","volume":"11","author":"Rachmilewitz","year":"1974","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib10","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V82.10.3204.3204","article-title":"Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes","volume":"82","author":"Repka","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0891-5849(94)00160-L","article-title":"Hydroxyl radical generation in beta-thalassemic red blood cells","volume":"18","author":"Grinberg","year":"1995","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00062752-200203000-00007","article-title":"Pathophysiology of thalassemia","volume":"9","author":"Schrier","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V71.4.1124.1124","article-title":"The effect of erythroid hyperplasia on iron balance","volume":"71","author":"Pootrakul","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib14","first-page":"288","article-title":"Management of cardiac complications in patients with thalassemia major","volume":"32","author":"Vecchio","year":"1995","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0037-1963(01)90029-0","article-title":"Clinical management of \u03b2-thalassemia major","volume":"38","author":"Wonke","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib17","first-page":"304","article-title":"Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine","volume":"32","author":"Giardina","year":"1995","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib18","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2008.01.006_bib19","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood.V86.5.2008.bloodjournal8652008","article-title":"Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo","volume":"86","author":"Shalev","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI119666","article-title":"Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia","volume":"100","author":"Browne","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2008.01.006_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/lc.1999.v133.a94241","article-title":"Deferiprone therapy in homozygous human \u03b2-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity","volume":"133","author":"De Franceschi","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib23","first-page":"115","article-title":"Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)","volume":"85","author":"Rombos","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2008.01.006_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mlc.2001.114105","article-title":"The controversial role of deferiprone in the treatment of thalassemia","volume":"137","author":"Richardson","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"9332","key":"10.1016\/j.exphem.2008.01.006_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2008.01.006_bib27","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions","volume":"107","author":"Neufeld","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14740338.6.3.235","article-title":"Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities","volume":"6","author":"Kontoghiorghes","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.exphem.2008.01.006_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-5793(79)80111-8","article-title":"Mobilization of iron from reticulocytes: identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent","volume":"97","author":"Ponka","year":"1979","journal-title":"FEBS Lett"},{"key":"10.1016\/j.exphem.2008.01.006_bib30","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/0006-2952(85)90142-X","article-title":"Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture","volume":"34","author":"Baker","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.exphem.2008.01.006_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0304-4165(88)90197-3","article-title":"Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes","volume":"967","author":"Ponka","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2008.01.006_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.1840150323","article-title":"Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture","volume":"15","author":"Baker","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.exphem.2008.01.006_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-4615-0593-8_11","article-title":"Pyridoxal isonicotinoyl hydrazone and its analogues","volume":"509","author":"Buss","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.exphem.2008.01.006_bib34","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0006-2952(02)01426-0","article-title":"Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes","volume":"61","author":"Buss","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.exphem.2008.01.006_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-2952(02)01551-4","article-title":"Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells","volume":"65","author":"Buss","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.exphem.2008.01.006_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1980.tb07147.x","article-title":"Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone","volume":"45","author":"Cikrt","year":"1980","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib37","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V91.11.4368","article-title":"Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone","volume":"91","author":"Blaha","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib38","doi-asserted-by":"crossref","first-page":"17953","DOI":"10.1016\/S0021-9258(18)38256-5","article-title":"Entrapment of purified alpha-hemoglobin chains in normal erythrocytes: a model for \u03b2-thalassemia","volume":"265","author":"Scott","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.01.006_bib39","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1172\/JCI116380","article-title":"Effect of excess \u03b1-hemoglobin chains on cellular and membrane oxidation in model \u03b2-thalassemic erythrocytes","volume":"91","author":"Scott","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2008.01.006_bib40","doi-asserted-by":"crossref","first-page":"9259","DOI":"10.1073\/pnas.92.20.9259","article-title":"Mouse model of human \u03b20 thalassemia: Targeted deletion of the mouse \u03b2maj- and \u03b2 min-globin genes in embryonic stem cells","volume":"92","author":"Ciavatta","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.exphem.2008.01.006_bib41","doi-asserted-by":"crossref","first-page":"19471","DOI":"10.1074\/jbc.M309989200","article-title":"Differential regulatory and compensatory responses in hematopoiesis\/erythropoiesis in \u03b1- and \u03b2-globin hemizygous mice","volume":"279","author":"Beauchemin","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.01.006_bib42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0021-9258(18)97685-4","article-title":"A new method for the preparation of \u03b1- and \u03b2-subunits of human hemoglobin","volume":"240","author":"Bucci","year":"1965","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.01.006_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0378-4347(00)84581-8","article-title":"Isolation of normal and variant hemoglobin chains","volume":"343","author":"Turci","year":"1985","journal-title":"J Chromatogr"},{"key":"10.1016\/j.exphem.2008.01.006_bib44","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood.V74.7.2542.2542","article-title":"Enhancement of erythrocyte superoxide dismutase activity: effects on cellular oxidant defense","volume":"74","author":"Scott","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib45","first-page":"470","article-title":"Effect of osmotic lysis-resealing on red cell structure and function","volume":"115","author":"Scott","year":"1990","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0003-9861(63)90042-0","article-title":"The preparation and characteristics of hemoglobin-free ghosts of human erythrocytes","volume":"100","author":"Dodge","year":"1963","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.exphem.2008.01.006_bib47","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.V71.4.876.876","article-title":"Excess heme in sickle erythrocyte inside-out membranes: possible role in thiol oxidation","volume":"71","author":"Kuross","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/je00054a044","article-title":"Synthesis of new acylhydrazones as iron-chelating compounds","volume":"33","author":"Edward","year":"1988","journal-title":"J Chem Eng Data"},{"key":"10.1016\/j.exphem.2008.01.006_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0304-4165(79)90100-4","article-title":"A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents","volume":"586","author":"Ponka","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2008.01.006_bib50","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0304-4165(83)90056-9","article-title":"A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe","volume":"757","author":"Huang","year":"1983","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2008.01.006_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0005-2736(83)90089-5","article-title":"Chelator-mediated iron efflux from reticulocytes","volume":"733","author":"Morgan","year":"1983","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2008.01.006_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2008.01.006_bib53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1242\/dev.105.4.733","article-title":"An assessment of the developmental potential of embryonic stem cells in the midgestation mouse embryo","volume":"105","author":"Beddington","year":"1989","journal-title":"Development"},{"key":"10.1016\/j.exphem.2008.01.006_bib54","unstructured":"Alzet Mini-Osmotic Pump Model 2001 Instruction and Specification Sheet, Alzet Technical Information Services. Cupertino, CA: DURECT Corporation."},{"key":"10.1016\/j.exphem.2008.01.006_bib55","series-title":"The American Society of Hematology Education Program Book","first-page":"40","article-title":"Iron deficiency and overload","author":"Beutler","year":"2003"},{"key":"10.1016\/j.exphem.2008.01.006_bib56","first-page":"112","article-title":"Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration","volume":"27","author":"Brittenham","year":"1990","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib57","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJM199812033392313","article-title":"Iron chelation with oral deferiprone in patients with thalassemia","volume":"339","author":"Tricta","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib58","first-page":"99","article-title":"Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal","volume":"98","author":"Hershko","year":"1981","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.exphem.2008.01.006_bib59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0022-3565(25)33072-7","article-title":"An in vivo evaluation of iron chelating drugs derived from pyridoxal and its analogs","volume":"221","author":"Johnson","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2008.01.006_bib60","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1191\/0960327105ht571oa","article-title":"Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits","volume":"24","author":"Sterba","year":"2005","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.exphem.2008.01.006_bib61","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1124\/jpet.106.111468","article-title":"Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity","volume":"319","author":"Sterba","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2008.01.006_bib62","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.V72.4.1278.1278","article-title":"Nonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation","volume":"72","author":"Kuross","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1042\/bj2200685","article-title":"Oxidative interactions between haemoglobin and membrane lipid: a liposome model","volume":"220","author":"Szebeni","year":"1984","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2008.01.006_bib64","series-title":"CRC Handbook of Methods for Oxygen Radical Research","first-page":"137","article-title":"Reactions of superoxide with hemoglobin","author":"Winterbourn","year":"1986"},{"key":"10.1016\/j.exphem.2008.01.006_bib65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF01703446","article-title":"Direct in vivo biotinylation of erythrocytes as an assay for red cell survival studies","volume":"63","author":"Hoffmann-Fezer","year":"1991","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib66","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1046\/j.1365-2141.1999.01441.x","article-title":"Iron proteins of duodenal enterocytes isolated from mice with genetically and experimentally altered iron metabolism","volume":"105","author":"Pountney","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.01.006_bib67","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.V98.3.525","article-title":"H ferritin knockout mice: a model of hyperferritinemia in the absence of iron overload","volume":"98","author":"Ferreira","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib68","series-title":"Handbook of Experimental Immunology","first-page":"56","article-title":"Genetic markers for following cell populations","author":"Ansell","year":"1986"},{"key":"10.1016\/j.exphem.2008.01.006_bib69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/09553009214551251","article-title":"Murine hematopoietic stem cells with long-term engraftment and marrow repopulating ability are less radiosensitive to gamma radiation than are spleen colony forming cells","volume":"61","author":"Ploemacher","year":"1992","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.exphem.2008.01.006_bib70","first-page":"1287","article-title":"In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia","volume":"89","author":"de Franceschi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2008.01.006_bib71","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2002-08-2382","article-title":"Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells","volume":"101","author":"Link","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.01.006_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0304-4165(84)90367-2","article-title":"The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone","volume":"802","author":"Ponka","year":"1984","journal-title":"Biochim Biophys Acta"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:26:00Z","timestamp":1759566360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X08000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0301472X08000428"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2008.01.006","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative treatment paradigm for thalassemia using iron chelators","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2008.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}